Home>About Us > What We Do

About Us

What We Do

Sichuan PriMed Shines Bio-tech Co., Ltd., headquartered in Chengdu, China, is a Non-human Primate CRO with extensive research experiences of 12 years (2005-2017). PriMed Shines provides highest service to our clients in our 400,000 ft2 fully AAALAC accredited facilities.
What We Do
Unique NHP Service

PriMed provides flexible collaboration models for client’s easy access to NHPs for their research purposes, including various induced and naturally occuring NHP disease models, co-development of NHP disease models, NHP samples and tissues, IP licensing, NHP expertise and professional consultancy, etc.

PriMed can also quickly evolve to specific research/disease areas through collaboration with our clients. PriMed capabilities generally cover:

-- Preclinical pharmacology studies of new drugs in NHP disease models
-- Co-development of designated human disease models in NHPs
-- Human disease research with NHP modeling
-- Tests of diagnostic or interventional methods for human diseases in relevant NHP models
-- Pharmacokinetic studies of new drugs in NHPs
-- Safety and preliminary toxicity studies of new drugs using NHP models
-- Translational researches based on NHP disease models
-- Customization and excogitation of short-term, periodical, and chronic NHP studies
-- Project management and auditing of NHP studies
-- NHP basal information, technique and procedure development, and relevant consulting services
-- NHP ethical and welfare development and disease management

Imaging Capability

-- Extensive OCT and FP experience.
-- Heidelberg Spectralis plus OCT.
-- Kowa Fundus Camera.
-- Fluorescence Angiography.
-- Roland Electroretinogram.
-- Imaging team with 10 employees (>2-yrs).
-- OCT focusing on retinal thickness, cyst and fluid, drusen.
-- Retinal thickness analysis: thickness Map, point counting.
-- FP focusing on retinal exudate, hemorrhage, morphological changes of vessels, optic nerve by SIVA software.

Translate preclinical findings sooner to help make smarter clinical decisions+
Our unique non-human primate models of CVMD, ophthalmic diseases, renal disease, liver disease and inflammation can better predict human response to therapeutic candidates and provide insight and understanding about a drug's efficacy, pharmacological profile, reducing failure in the clinic, and supporting the selection of the right patients for the right therapy.
The primary reason for late stage drug failure in clinical trials is the inability to document improvement in outcomes. Therefore, PriMed’s NHP disease models can be used at various stages of preclinical research to help you get answers on key efficacy readouts earlier and gain critical information for your “Go / No-Go” decision.
Hyperlipidemia+
PriMed has the world’s largest collection of well-characterized naturally dysmetabolic rhesus monkeys (n=700), which mirrors every aspect of the human disease including disease progression, obesity, dyslipidemia and complications such as nephropathy, retinopathy and heart failure. Using animal models with such a close resemblance to human disease should result in the most reliable preclinical data.
Spontaneously Heart Failure Non-human Primate+
PriMed assessed cardiac function by GE vivid S5 color doppler ultrasound and 3T MRI in our spontaneously dysmetabolic NHPs. Criteria of NHP heart failure including heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) has been set up in our colony. We have about 200 rhesus monkeys with systolic dysfunction and diastolic dysfunction and all these monkeys have long term (> 5 years) medical records. Our extensive Echo and MRI experience with monkey heart testing can help our clients gain valuable insight and understanding into their candidates.
Spontaneously Diabetic Non-human Primate+
Non-human primate (NHP) models of diabetes are the most clinically translatable animal model in T2DM. NHP models that spontaneously develop diabetes show all of the characteristics of T2DM patients at different stages of the progressive disease, and also develop late stage complications such as diabetic nephropathy, retinopathy et al.
NAFLD/NASH+
The non-human primate NAFLD/NASH model, permitting both repeated liver biopsies and imaging studies, provides new opportunities to understand the pathogenesis as well as to examine in detail both the progression of the disease and its response to new therapeutic agents. PriMed has a large collection of rhesus NAFLD/NASH NHP models, which mirror every aspect of the human disease including steatosis, inflammation and ballooning. Diagnostic criteria according to human has been established by dual energy CT and histopathology of ultrasound-guided liver biopsy. PriMed has demonstrated for the first time that, like human disease, obese, dysmetabolic, and diabetic NHPs also develop NAFLD/NASH.

Connect